Mineralys Therapeutics Quarterly Income Statement
NASDAQ: MLYSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
23.37+0.99 (+4.42%)
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Mineralys Therapeutics revenue and earnings
Mineralys Therapeutics reported a net loss of $241.1 million, compared with a loss of $43.3 million a year earlier. Diluted earnings per share came in at -$2.85.
Summary generated from market data by MetaCap's automated system. Methodology
Mineralys Therapeutics income statement (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Expenses | 246.04M | 45.34M | 38.28M | 41.13M | 46.75M | 44.45M | 51.77M | 60.11M | 45.17M | 35.36M | 27.71M | 26.27M |
| Research & Development | 221.38M | 24.36M | 24.40M | 31.45M | 38.28M | 37.88M | 44.57M | 53.98M | 39.27M | 30.75M | 23.68M | 22.50M |
| Operating Income | -246.04M | -45.34M | -38.28M | -41.13M | -46.75M | -44.45M | -51.77M | -60.11M | -45.17M | -35.36M | -27.71M | -26.27M |
| Other Income (Expense) | 4.97M | 6.00M | 6.05M | 4.20M | 3.47M | 2.24M | 2.82M | 3.76M | 4.15M | 3.85M | 3.32M | 3.51M |
| Income Tax | — | — | 0 | — | — | — | — | — | — | — | — | — |
| Net Income | -241.07M | -39.34M | -32.23M | -36.93M | -43.27M | -42.21M | -48.95M | -56.34M | -41.01M | -31.51M | -24.39M | -22.76M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| EPS (Basic) | -2.85 | -0.47 | -0.32 | -0.52 | -0.66 | -0.79 | -1.00 | -1.13 | -0.83 | -0.70 | -0.60 | -0.57 |
| EPS (Diluted) | -2.85 | -0.47 | -0.32 | -0.52 | -0.66 | -0.79 | -1.00 | -1.13 | -0.83 | -0.70 | -0.60 | -0.57 |
| Shares Outstanding (Basic) | 84.73M | 82.83M | — | 70.59M | 65.45M | 53.16M | — | 49.82M | 49.36M | 44.90M | — | 39.93M |
| Shares Outstanding (Diluted) | 84.73M | 82.83M | — | 70.59M | 65.45M | 53.16M | — | 49.82M | 49.36M | 44.90M | — | 39.93M |
| EBITDA | -246.03M | -45.33M | -38.27M | -41.12M | -46.73M | -44.43M | -51.75M | -60.09M | -45.16M | -35.35M | -27.71M | -26.27M |
This table shows 12 quarterly periods of Mineralys Therapeutics's income statement, from Q2 2026 back to Q3 2023, across 11 line items including operating expenses, research & development, operating income. Values in USD; B = billions, M = millions. Fiscal periods follow MLYS's reporting calendar. What is a income statement?